What is the Role of Triglyceride-glucose Index as a Predictive Marker for Insulin Resistance in Pre Diabetic Chronic Kidney Disease Patients?

The Role of Triglyceride-glucose Index as a Predictive Marker for Insulin Resistance in Pre Diabetic Chronic Kidney Disease Patients.

The aim of this study is to evaluate the role of the triglyceride-glucose (TyG) index as a predictive marker for insulin resistance in pre-diabetic patients with chronic kidney disease (CKD), and to investigate its potential utility as a simple, non-invasive alternative to traditional insulin resistance assessment methods.

Study Overview

• Status: Not yet recruiting
• Conditions: Chronic Kidney Disease; Pre Diabetes
• Intervention / Treatment: Diagnostic test: Triglyceride-glucose index

Detailed Description

Diabetes mellitus remains a major public health challenge worldwide due to its increasing prevalence and associated complications, particularly when undiagnosed in its early stages. Early identification of individuals at high risk is essential for timely intervention to delay or prevent disease onset. Traditional diagnostic tools may miss early metabolic disturbances, necessitating more sensitive and accessible biomarkers.

The triglyceride-glucose (TyG) index, derived from fasting plasma triglycerides and glucose, has recently emerged as a simple, reliable, and cost-effective surrogate marker for insulin resistance. Its utility has been validated in multiple populations, showing strong associations with metabolic dysfunction and future development of diabetes.

Renal dysfunction is frequently associated with alterations in glucose and lipid metabolism, even before overt diabetes develops. However, the diagnostic accuracy of traditional risk markers may be compromised in the context of impaired kidney function. The TyG index offers potential advantages due to its independence from insulin measurements and ease of calculation.

Despite growing evidence on the predictive role of the TyG index, limited data exist regarding its performance across different levels of kidney function. Investigating its diagnostic value in patients with and without renal impairment may provide a valuable tool for early diabetes risk assessment and targeted preventive strategies.

• Study Type: Observational
• Enrollment (Estimated): 60

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adults aged ≥18 years with medical history free from renal dysfunction or with renal dysfunction (CKD stages 2_5 based on KDIGO guidelines)

Description

Inclusion Criteria:

• Adults aged ≥18 years

Patients with medical history free from renal dysfunction

Patients with renal dysfunction (CKD stages 2_5 based on KDIGO guidelines)

No previous diagnosis of diabetes mellitus

Provided informed consent

Exclusion Criteria:

• Known type 1 or type 2 diabetes mellitus

Acute kidney injury

Use of steroids or medications that affect glucose and lipid metabolism

Pregnancy

Active infections

Malignancy

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Diagnostic performance of TyG index	Diagnostic performance of TyG index in predicting prediabetics and diabetic patients.	2 years

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2026
• Primary Completion (Estimated): January 1, 2028
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: December 1, 2025
• First Submitted That Met QC Criteria: December 1, 2025
• First Posted (Actual): December 12, 2025

Study Record Updates

• Last Update Posted (Actual): December 12, 2025
• Last Update Submitted That Met QC Criteria: December 1, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Chronic Disease; Disease Attributes; Metabolic Diseases; Glucose Metabolism Disorders; Renal Insufficiency; Hyperglycemia; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Renal Insufficiency, Chronic; Glucose Intolerance
• Other Study ID Numbers: TyG-CKD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No